Proteinase K Market

Proteinase K Market Size (2024 to 2029)

The Proteinase K market size is worth USD 56.83 Million in 2024 and is estimated to reach USD 80.15 Million by 2029 with a CAGR of 5.9% during the forecast period. 

Proteinase K is an enzyme known as a serine protease that breaks down proteins into hydrolyzing peptide bonds. Proteinase K is a broad-spectrum protease enzyme that can digest a wide variety of proteins, including the ones that are resistant to other proteases. Proteinase K is widely used in the analysis of protein structure and function as it helps remove the nucleases that degrade the DNA and RNA. Proteinase K is used for sample preparation in various research and diagnostic applications as it is stable in a wide range of pH and temperature and withstands many detergents and denaturing agents. Proteinase K is prominently used in molecular biology and biochemistry applications for breaking down structural proteins and enzymes. 

Market Drivers:

The rising prevalence of chronic immunogenic and hereditary diseases related to gene sequencing, DNA extraction, and others drives the market value growth for Proteinase K. The growing research regarding the innovations in cell separation methods by diagnostic labs and research laboratories is boosting the adoption of Proteinase K for DNA and RNA extraction. Proteinase K is used in the sample preparation for long-read sequencing as it completes the sample processing in 30 to 40 minutes rather than 5 to 6 hours for DNA pieces of 40kb to 50kb in length. Proteinase K has a primary role in the purification of DNA, and these techniques are expected to fuel the demand for proteinase K in the global market. According to an article published in June 2022 in the Journal of Functional Polymers, Proteinase K can be used along with the antimicrobials, enhancing antimicrobials penetration through biofilm. It enhances the ability to disperse over the biofilm of methicillin-resistant staphylococcus aureus by inducing the entry of an antimicrobial agent. 

The increasing government initiatives for promoting genomics research are due to growing sequencing technology applications. The government is funding research and development activities, fueling the growth of Proteinase K's market share. For instance, in April 2021, the government of Singapore launched the National Precision Medicine Stratto to analyze better how phenotypic, genomic, clinical factors and lifestyle affect the country's health—increasing investments by the market players in R&D for seeking innovations in cell separation and sample sequencing methods. 

There are growing benefits of Proteinase K in diagnostic applications as these enzymes are associated with in-vitro diagnostics. Proteinase K can be used as a supplement in molecular diagnostic applications such as NGS and PCR. Increasing demand for the NGS and PCR is expected to propel the growth of demand for the proteinase K. Proteinase K is used in the DNA extraction step before the PCR to improve the DNA sample quality.

To conduct the research effectively, market key players collaborate with clinic search organizations to expand their product portfolio, creating market growth opportunities during the forecast period. The growing demand for the proteinase K in Point-of-Care diagnostic testing is estimated to fuel the market value growth during the forecast period. Various POC devices are developing with advanced technology, influenced by the increasing demand for proteinase K over the forecast period. 

The increasing advancements in proteomics have led to innovative applications in protein library generation for genomic studies where proteinase K plays a crucial role in RNA and DNA purification processes. The rising prevalence of chronic diseases like cancer, cardiovascular diseases, and blood disorders influences the market expansion in the forecast period

Market Restraints:

The growing availability of alternative proteases and other substitutes for DNA purification is expected to hamper the market growth. Some alternatives offer better benefits compared to proteinase K, such as broad enzymatic activity and ease of inactivation, limiting the demand for proteinase K. Various advanced technologies are launched for DNA purification, which restrains the proteinase K market value. 

Another restraining factor is the availability of new alternate technologies for protein purification, where the new technologies give rapid results compared to the Proteinase K. The ease of availability of these kits is of all the requirements necessary for isolating the pure DNA genome effect. Alternative products are readily available at low costs compared to Proteinase K, hindering market growth.

Proteinase K leads to autolysis at low concentrations, whereas it is stable at higher concentrations, which is a challenging factor for market expansion. Overusing proteinase K leads to the breakdown of the target sample, which results in the loss of activity. Proteinase K is well-known for its ability to inactivate DNases and RNases, which may sometimes damage the desired nucleic acid samples during extraction. 

Impact of COVID-19 pandemic on the global proteinase k market:

The Pandemic had a positive impact on the Proteinase K market as COVID-19 boosted the demand for Proteinase K. According to an article published on PLOS in 2021, Proteinase K treatment followed by the thermal shock for RNA extraction of COVID-19 is faster and more cost-effective. Many companies use Proteinase K to develop PCR-testing COVID-19 diagnostic kits, prompting market growth. These developments and applications during the Pandemic are increasing the adoption of Proteinase K by raising market revenue. 

REPORT COVERAGE:

This research report on the global proteinase k market has been segmented and sub-segmented into the following categories.

Proteinase K Market-By Form:

• Powder Form
• Liquid Form

The powder segment held the largest share of 54.5% in the global market in 2023 and is expected to dominate over the forecast period. The domination is due to the lyophilization techniques, where the lyophilization powder has high stability with a longer shelf-life. These advantages help in inexpensive shipping where the lyophilization does not reduce the activity of the Proteinase K. All these powder advantages drive the market growth in this segment. 

The liquid segment is expected to increase with significant CAGR over the forecast period due to more convenience in usage. The liquid form is a timesaver as the powder form takes time to solubilize. Liquid form is advantageous in the large production batches, which is estimated to fuel the market growth during the forecast period. 

Proteinase K Market-By Therapeutic area:

• Infectious Diseases
• Diabetes
• Oncology
• Cardiology
• Neurology

The infectious diseases segment held the largest share of 31.5% 2023 in the global market revenue. Infectious diseases such as HIV, tuberculosis, and malaria in the low- and mid-income regions are projected to enhance the players to develop the products. For Instance, QIAGEN offers Proteinase K, isolated from the fungus Tritirachium. It isolates the DNA and RNA from the samples during viral and bacterial infection diagnosis. 

The neurology segment is estimated to have significant growth during the forecast period. Various therapies are still under development for neurology, such as enzyme replacement, small molecule therapies, gene-replacement therapies, and others, which are estimated to enhance market size growth over the forecast period. 

Proteinase K Market-By Application:

• Purification of DNA & RNA
• In situ Hybridization
• Mitochondria Isolation
• Enzyme Removal

The Purification of DNA and RNA segment dominated with the most significant market share of 58% in 2023. They maintained the domination over the forecast period due to the rising prevalence of infectious diseases across the world. Proteinase K is widely used in multi-stages to purify DNA & RNA. They are increasing chronic infectious diseases demand techniques that boost market growth. Purification of genomic DNA and RNA is common in CROs and biotechnology companies. 

The Situ Hybridization segment is expected to expand with a significant CAGR during the forecast period. Increasing the adoption rate due to essential benefits with rapid, accurate results drives market growth. 

Proteinase K Market-By End-User:

• Contract Research Organizations (CROs)
• Academic Institutes
• Biotechnology Companies
• Diagnostic Laboratories

The Contract Research Organizations segment dominates the global market with the largest market share, as many key players are collaborating with CROs to increase effectiveness in research procedures. Biotechnological companies showed a significant growth rate and are expected to grow steadily in the forecast period. The growing application of in situ hybridization in biotechnological companies is estimated to drive the market in the coming years. 

The academic institutes segment is projected to grow significantly over the forecast period. Academic institutes offer integrated services for in-vitro diagnostic clinical research. 

Proteinase K Market-By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

North American region dominated the global market revenue with the most significant share of 46.2% in 2023. The region's massive demand for Proteinase K and the rising prevalence of chronic and infectious diseases drive the market revenue. During the Pandemic, the FDA issued Emergency Use Authorizations for in vitro COVID-19 laboratory tests, which fueled the market expansion. High applications of enzymes during RT-PCR for detecting SARS-CoV-2, where these developments enhance the market revenue in the region. 

Europe held the second dominant position in the global market due to its advanced healthcare infrastructure, which adopts cost-effective and efficient methods. The rising government initiatives and establishing of prominent regional research centers are boosting market value growth. 

Key Market Players:

Merck KGaA, QIAGEN, Thermo Fisher Scientific Inc, F. Hoffmann-La Roche Ltd, Abcam plc, Agilent Technologies, Minerva Biolabs GmbH, Takara Bio Inc, Biocatalysts, New England Biolabs are some of the key market players.

Recent Market Developments:

• In May 2023, QIAGEN introduced its portfolio of high-quality enzymes as individual products for gaining industrial consumers and researchers across the globe. This step made QIAGEN a one-stop solution for all the research requirements. 
• In December 2022, Arctic Zymes Technologies announced that they upscaled the production of their proteinase. The upscaled proteinase is expected to meet the industry demand for proteinase. 
• In February 2022, Merck KGaA acquired Exelead and announced its plans to expand the company portfolio, influencing growth. 
• In April 2022, Thermo Fisher Scientific Inc. announced its collaboration with Matrix Clinical Trails to enhance its clinical research solutions and boost the market growth for decentralized trail solutions.